Serina Therapeutics, Inc. (SER) NYSE

4.17

+0.06(+1.46%)

Updated at March 14 04:00PM

Currency In USD

Serina Therapeutics, Inc.

Address

601 Genome Way

Huntsville, AL 35806

United States of America

Phone

256 327 9630

Sector

Healthcare

Industry

Biotechnology

Employees

9

First IPO Date

January 21, 2000

Key Executives

NameTitlePayYear Born
Mr. Steven A. LedgerChief Executive Officer & Director237,5001959
Dr. Randall W. Moreadith M.D., Ph.D.Chief Development Officer433,8801955
Dr. Srini TenjarlaSenior Vice President of Chemistry, Manufacturing & Controls and Formulation0N/A
Dr. Balkrishan Gill Ph.D.Executive Chairman01965
Dr. J. Milton Harris Ph.D.Co-Founder, Director Emeritus & Chair of Scientific Advisory Board01941
Mr. Gregory S. CurhanChief Financial Officer01962

Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.